Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 18,400 shares, a growth of 70.4% from the June 30th total of 10,800 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 52,400 shares, the short-interest ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Trinity Biotech in a report on Sunday, July 21st. They set a “buy” rating on the stock.

Trinity Biotech Price Performance

Shares of TRIB opened at $2.86 on Friday. The business’s 50 day moving average price is $2.36 and its 200-day moving average price is $2.22. Trinity Biotech has a 52 week low of $1.49 and a 52 week high of $5.10.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. The firm had revenue of $14.70 million during the quarter. On average, analysts forecast that Trinity Biotech will post -2.17 EPS for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.